Table 3 Proportion of prescribed maximum daily dose of pregabalin during follow-up
From: Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study
| Â | Â | Maximum dose prescribed | Â | ||||
|---|---|---|---|---|---|---|---|
Indications | Mean (SD) | < 150 mg | > = 150 mg ~ < 300 mg | > = 300 mg ~ < 450 mg | > = 450 mg ~ < 600 mg | > = 600 mg | Sum |
Herpes zoster | 147.2 (100.3) | 11,257 (32.2) | 21,181 (60.7) | 1986 (5.7) | 359 (1) | 136 (0.4) | 34,919 |
Diabetic peripheral neuropathic pain | 131.2 (93) | 5900 (44.1) | 6789 (50.8) | 580 (4.3) | 76 (0.6) | 24 (0.2) | 13,369 |
Fibromyalgia | 139.2 (89) | 8323 (39.5) | 11,332 (53.8) | 1039 (4.9) | 294 (1.4) | 63 (0.3) | 21,051 |
Epilepsy | 200.9 (145.4) | 763 (23.1) | 1717 (52) | 504 (15.3) | 247 (7.5) | 70 (2.1) | 3301 |
Other musculoskeletal diseases | 131.1 (72.2) | 9825 (40.6) | 13,483 (55.7) | 749 (3.1) | 134 (0.6) | 36 (0.1) | 24,227 |
Others | 138.8 (89.1) | 6799 (38.7) | 9708 (55.3) | 823 (4.7) | 184 (1) | 56 (0.3) | 6433 |
Total | 140.7 (92.8) | 42,867 (37.5) | 64,210 (56.1) | 5681 (5.0) | 1294 (1.1) | 385 (0.3) | 114,437 |